Eurofins CALIXAR
Created in 2010
- BETA
Up & running (A)
Existing signals show a regular activity Social networks
135 3,948Activities
Technologies
Entity types
Location
60 Av. Rockefeller, 69008 Lyon, France
Lyon
France
Employees
Scale: 11-50
Estimated: 18
SIREN
530424670Engaged corporates
11
6 7Added in Motherbase
5 years, 7 months ago
biotech Value proposition
Native and functional membrane therapeutic targets for improving Drug and Vaccine Discovery
To contact us : contact@calixar.com
CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens.
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
Membrane Protein, Vaccine discovery, Structure Based Drug Design, Target validation, GPCR, Ion channel, Transporter, Therapeutic antibodies, Therapeutic Targets, Isolation, Expression, Purification, Crystallization, Stabilization, Extraction, Native receptors, and ChemistryOriginal language
Native and functional membrane therapeutic targets for improving Drug and Vaccine Discovery
To contact us : contact@calixar.com
CALIXAR, is a biotech company specialized in the functional and native isolation of complex membrane therapeutic targets and antigens.
We develop and implement chemistry and biochemistry tools to isolate in solution - with the highest purity levels - full-length membrane proteins, while keeping their structural and functional integrity. Our approach represents the opportunity for pharmaceutical companies to start and work with high quality targets or antigens before developing antibodies, formulating vaccines and/or discovering a primary lead through Structure Based Drug Design or High Throughput Screening assays.
As membrane proteins represent more than 60% of pharmaceutical drug targets, to keep their native conformation during the extraction from membrane cells and solubilization is crucial.
Our technological platform preserves the original structure of membrane proteins such as GPCRs, Ion channels, Transporters, Viral targets, etc.) or others native receptors acting as drug targets or antigens. As a result, this most accurate targeting helps biotechs, academic teams, pharmaceutical industries to develop highly potential drugs, bio drugs and vaccines and consequently saves significant time and money in further clinical stages.
By using original chemistry and specific approaches designed on demand, we develop new tools and protocols for the identification, expression, extraction, purification and crystallization of these membrane proteins/antigens from cells or from endogenous materials (virus, bacteria, primary cells, organs, etc.).
For SBDD/FBDD approaches, we carry out crystallization tests and structure determination of these native targets starting from their full-length and functional version without any point mutations or deletions.
CALIXAR sets up specific R&D programs with its customers using classical and flexible business model: Fee for service, Risk sharing, Exclusivity option and Licensing out.
Eurofins Calixar: high-quality membrane protein target experts
https://www.calixar.com/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Ministère de l'Enseignement supérieur et de la Recherche Government Administration | Other 17 Dec 2023 | | |
 Eurofins Scientifique Biotechnology, Biotechnology Research | Eurofins Scientifique Biotechnology, Biotechnology Research | Other 1 May 2023 | | |
 Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Other 5 Mar 2023 | | |
 CNRS Innovation Research, Research Services | CNRS Innovation Research, Research Services | Other 17 Mar 2023 | | |
 Elsevier Publishing, IT Services and IT Consulting | Elsevier Publishing, IT Services and IT Consulting | Other 22 Jan 2023 | | |
 CNRS Research, Research Services | CNRS Research, Research Services | Other 24 Feb 2023 | | |
 CCI de Grenoble Chamber of commerce, Government Administration | CCI de Grenoble Chamber of commerce, Government Administration | Other 19 Apr 2023 | | |
 Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Région Auvergne-Rhône-Alpes National and local authorities, Government Administration | Other 27 Jan 2023 | | |
 XAnge Startup accelerator & VC, Venture Capital and Private Equity Principals | XAnge Startup accelerator & VC, Venture Capital and Private Equity Principals | Not capitalistic Not partnership Event 2 Aug 2017 | | |
 Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Lyonbiopôle Auvergne-Rhône-Alpes Public business cluster, Biotechnology, French Cluster, Biotechnology Research | Capitalistic Partnership Not event 12 Apr 2021 | | |